If a drug that simultaneously modulates PGC-1α and ERRα is developed, a new drug that exhibits multiple functions for preventing bone marrow adiposity, improving bone mineral density, and reducing osteoporosis as well as improving systemic lipid metabolism in postmenopausal women can be presented. This evidence concerns the gene PPARGC1A and osteoporosis.